February 10, 2020 Clinical Research/Diagn. Mass Spectrometry

Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry

New Center of Excellence to Advance Highly Multiplexed Tissue Imaging in Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will establish a new Center of Excellence (CoE) for Imaging Mass Cytometry™ at Georgetown... Read more

December 10, 2019 Clinical Research/Diagn. Life Science Tools Mass Spectrometry Product Launch

Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging

Delivering the Largest Commercially Available Collection of Pathologist‑Verified Antibodies for Imaging Mass Cytometry SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced the availability of more than 100 pathologist-verified Maxpar® antibodies for use with Imaging Mass Cytometry™ (IMC™) on the Hyperion™ Imaging System. This expanding collection now includes... Read more

September 24, 2019 Clinical Research/Diagn. Mass Spectrometry Product Launch

Fluidigm Becomes the First Company to Enable 50-Plex Cytometry Panels with the Release of Seven New Metal Antibody Labels

Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research SOUTH SAN FRANCISCO, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has launched seven new cadmium metal labeling kits for use with mass cytometry. The newly available... Read more

September 10, 2019 Clinical Research/Diagn. Licensing, IP, and Legal Mass Spectrometry

Fluidigm Files Patent Infringement Suit Against IONpath

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has filed new legal action in the United States District Court for the Northern District of Californiaseeking to stop the infringement of its patented technology by IONpath. In... Read more

August 27, 2019 M&A, Partnerships

Fluidigm and the Icahn School of Medicine at Mount Sinai Collaborate on Landmark Single-Cell Study of the Human Epigenome

Aug 27, 2019 Mount Sinai selects Fluidigm single-cell microfluidics systems to identify epigenetic changes from environmental agents in study funded by the U.S. Department of Defense SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has... Read more

August 1, 2019 PR/Corporate

Jonathan Day Named VP, Commercial Operations, Americas

Seasoned Commercial Leader with Track Record in Life Sciences and Diagnostics SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Jonathan Day as Vice President, Commercial Operations, Americas. Day will be responsible for leading all commercial activities in the Americas, furthering market adoption of Fluidigm products, particularly in the growing scientific community studying the human immune... Read more

August 1, 2019 Life Science Tools

Fluidigm to Automate RNA Sequencing Library Preparation Using Microfluidics Technology

Automated Nanoscale RNA Library Preparation for Next-Generation Sequencing to Deliver Significant Savings and Workflow Efficiency for the Molecular Laboratory SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced it will introduce an automated RNA sequencing (RNA-seq) library preparation... Read more

July 25, 2019 PR/Corporate

Bill W. Colston Named to Fluidigm Board of Directors

Jul 25, 2019 Senior Biotechnology Leader with Broad Expertise in Life Science and Digital Health SOUTH SAN FRANCISCO, Calif., July 25, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Bill W. Colston to the company’s Board of Directors. Colston is President of iCarbonX and has more than 30 years of experience across a range of innovative life... Read more

June 19, 2019 Cell Analysis Tools Clinical Research/Diagn. Product Launch

Fluidigm Introduces Three Imaging Mass Cytometry Panel Kits and Advanced CyTOF Software to Accelerate Immuno-Oncology Research

PDF Version Illuminating the diversity of immune cell phenotypes and function in the context of the tumor microenvironment, all in a single scan SOUTH SAN FRANCISCO, Calif., June 19, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it... Read more

June 17, 2019 Cell Analysis Tools Clinical Research/Diagn. Product Launch

Fluidigm Scales Highly Multiplexed Cell Analysis with Introduction of Seven New Metal Markers

Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research SOUTH SAN FRANCISCO, Calif., June 17, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will introduce seven new cadmium metal labeling kits for mass cytometry in Q3. Representing... Read more